Adhezion seals deal on more funds for series A
This article was originally published in Clinica
Executive Summary
Adhezion Biomedical, a Wyomissing, Pennsylvania-based developer of cyanoacrylate-based medical adhesives and antimicrobial sealants, has raised an additional $2.1m in series A financing, bringing the total investment received to $5.25m. The second tranche of funds came from Liberty Venture Partners. Adhezion’s flagship product is SurgiSeal, which is being introduced to European markets and is pending US FDA approval. Other products in the pipeline include DermaSeal, a woundcare product, and FloraSeal, an advancedantimicrobial sealant.